# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹251 Cr Q3 (+27%) · ₹754 Cr 9M (+32%) * **EBITDA:** ₹66 Cr Q3 (+43%, 310 bps expansion) · ₹218 Cr 9M (+76%, 720 bps expansion) * **PAT:** ₹37 Cr Q3 (+48%, 220 bps expansion) · ₹130 Cr 9M (+101%, 590 bps expansion) * **Cash PAT (9M):** ₹166 Cr (+73%) * ROCE / ROE: 38.4% / 29.1% (Dec-25) · Debt/Equity: 0.3x ## B. Revenue Growth * **Strong Momentum:** Robust double-digit revenue growth in Q3 and 9M driven by operating leverage and market demand, despite geographic timing mismatches in U.K. and Dubai. * **Timing-Driven Pressure:** Q3 financials weighed by high exhibition costs (CPHI, POD, PDA) with no corresponding revenue, and delayed milestone-based income recognition into Q4. * **Cost Recognition Lag:** Unbooked consolidated revenue linked to projects where **labor costs of ₹90 lakhs–₹1 crore** were incurred upfront, creating temporary margin drag. ## C. Profit Margins * **Significant Margin Expansion:** Sustained EBITDA and PAT margin improvement over 9M reflects operating efficiency, despite near-term headwinds from elevated admin and selling expenses. * **Expense Pressures:** Margin performance in Q3 impacted by setup costs for Abu Dhabi and global locations, along with delayed one-time income recognition now expected in Q4. * **Healthcare Margin Recovery:** Sequential gross margin improvement in healthcare (Q2: ~55% → Q3: ~56%); further expansion expected in Q4, though normalization delayed until Q1 due to **high-speed line qualification**. ## D. Cash Flow * **Healthy Cash Conversion:** Cash PAT grew 73% YoY to ₹166 Cr over 9M, outpacing net income growth, signaling improved working capital and earnings quality. ## E. Balance Sheet * **Leveraged Structure:** High debt/equity ratio of 3x and low fixed asset turnover (0x) reflect capital-intensive setup phase, with ROCE and ROE still subdued at 4% and 1%, respectively. * **One-Time Costs:** **INR90 lakhs–INR1 crore** expensed for Labor Code implementation (gratuity, leave encashment), adding to quarterly cost burden. --- # 2. Segment & Revenue Mix ## A. Key Figures * **Healthcare Revenue:** **₹280 Cr** (9M FY'26) (+158%) · **₹104 Cr** (Q3 FY'26) (+136% YoY) * **Consumer Revenue:** **₹409 Cr** (9M FY'26) (-1%) · **₹123 Cr** (Q3 FY'26) (-13% YoY) * **Industrial Revenue:** **₹65 Cr** (9M FY'26) (+36%) * **Export Contribution:** **~71%** of total revenue (Q3 & 9M FY'26) ## B. Healthcare Segment * **Strategic Pivot Accelerating:** Healthcare now represents **42% of total revenue**, up from 21% last year, reflecting a major shift in business mix and strong execution. * **New Wins & Capacity Buildout:** Secured 2 new GLP-1 customers and 2 pen injector contracts with Global Pharma, supporting continued scaling and technological differentiation. ## C. Consumer Segment * **Demand Headwinds Persist:** Consumer segment decline attributed to weakening end-market demand in Europe and the U.S., with recovery tied to broader macroeconomic improvement. * **Long-Term Upside in Electronics:** New product mandates and entry into consumer electronics—targeting high-value components for India-based final assembly—position for future growth amid China+1 shifts. ## D. Industrial Segment * **Solid Growth Trajectory:** Industrial revenue grew at a strong double-digit pace, driven by new client ramp-ups and expansion into power tools and LED lighting applications. ## E. Export Dynamics * **Sustained Global Franchise:** Exports maintained dominant share of revenue (~71%), underpinned by international demand across healthcare and industrial verticals. * **Semiconductor Export Optionality:** Management highlighted potential for exporting semiconductor casings beyond domestic needs, though no concrete plans disclosed. --- # 3. Capacity & Production ## A. Key Figures * **Polymer Processing Volume:** **5,541 tonnes** Q3 FY'26 (–12%) · **19,209 tonnes** 9M FY'26 (+4%) * Machine Utilization: 47.1% Q3 FY'26 · 47.8% avg 9M FY'26 * **Current & Planned Capacity:** **80 million pens** total post-India expansion · **150 million pens** with UAE facility ## B. India Expansion * **Phased Ramp-Up:** Second production line arrival expected end-April to early May 2026, with commercial production starting March 2026 and scale-up from April 2026, reflecting accelerated internal planning. * **Qualification Timeline:** First line under final qualification with immediate supply post-approval; second line to be qualified by end of July 2026, later revised to Q2 2027 for full operational status. * **Strategic Shift:** Relocation of a 5-crore pen line to India due to execution challenges abroad, underscoring preference for domestic control in rapid deployment scenarios. ## C. UAE Facility * **Strategic Global Footprint:** New Abu Dhabi facility to enter operation by **Q4 FY28**, targeting **5 crore pen/auto-injector units annually**, enhancing access to regulated markets with stronger IP protection. * **Technology & Supply Chain Rationale:** UAE plant to use **16-cavity molds** for higher efficiency and reduce reliance on imported resin and equipment, countering Chinese competition in key markets like India. * **Commercial De-Risking:** Expansion is **50–60% secured** on capacity commitments and expected to be fully contract-backed within 18 months, minimizing demand risk. * **Funding & Scalability:** Investment of **AED13–15 Cr (₹300–350 Cr)**; government support under discussion; additional capacity would be required for large-volume innovator deals. ## D. Line Qualification * **Internal Process Focus:** Line qualification is a rigorous internal Shaily-led procedure involving **25–30 operations at 80 parts per minute**, not a regulatory or customer approval, ensuring technical readiness. * **Speed & Complexity:** High-speed pen assembly line nearing qualification, with ramp-up to **50–60 parts per minute** expected within one month post-approval. * **Client Milestone:** Qualification for consumer electronics client on track for completion by end of current month or early March, signaling progress in diversification. ## E. Utilization Rates * **Near-Term Constraints:** Despite 9-month volume growth, Q3 polymer processing declined 12%, and machine utilization dipped to **1%**, highlighting transitory underuse amid program ramp-up cycles. * **Operational Challenges:** Current lines running at **60–70 parts per minute** with **30% rejection rates** due to process inefficiencies, not final quality, indicating scope for yield improvement. * **Capacity Outlook:** With plans to supply **3 crore pens** against existing constraints and new capacity only online by end-FY28, near-term tightness persists, though no overcapacity is anticipated due to demand-linked expansion. --- # 4. Product & Pipeline Progress ## A. Key Figures * **GLP-1 Commercial Supply:** Active in **5 regions** (Canada, Brazil, India, Middle East, Turkey) * **Production Capacity:** **Two dedicated lines** with **16-cavity molds** for GLP-1 products at Baroda facility * Semiconductor Timeline: Commercial supply begins small-scale next fiscal, large-scale dependent on 12-month domestic fab ramp-up ## B. GLP-1 Injectors * **Commercial Momentum:** Supply now live across five international markets, signaling successful scale-up and regulatory alignment. * **Innovation Pipeline:** Advanced discussions underway for **two novel GLP-1 molecules** via Axiom, with potential partnership closure this calendar year. * **Clinical Advantage:** Injectable GLP-1s maintain superiority over oral versions due to **significantly higher bioavailability** and lower API burden. ## C. Consumer Electronics * **Strategic Focus:** Portfolio shift toward **high-complexity, precision hybrid components** (metal-plastic combinations), targeting premium segments. ## D. Semiconductor Casings * **Market Entry:** Initial shipments expected in new fiscal year, but meaningful volume hinges on **domestic semiconductor manufacturing ramp-up**. --- # 5. Customer & Contract Metrics ## A. Key Figures * Customer Commitments (India Expansion): 50M-unit capacity fully backed · full utilization expected within 24 months * **Market Share (Canada GLP-1):** **65–75%** among first 6–8 filers * Potential Demand (Innovator Clients): 50–100 million pens expected, timing uncertain * **Revenue Recognition Period (U.K./Abu Dhabi):** **12–21 months** over milestones ## B. Take-or-Pay Contracts * **Capacity Backed by Take-or-Pay Agreements:** Abu Dhabi and India expansions supported by multi-year, minimum volume take-or-pay contracts, de-risking capex despite lack of capital advances. * **Flexible but Binding Terms:** Contracts include **advance payments of 20–40%** and allow limited flexibility during customer need, but remain financially binding in a supply-constrained market. * **No Clear Annual Volumes for Key Clients:** Despite new client onboarding, existing volumes have declined, signaling potential churn or shifting demand. ## C. Key Customer Wins * **Dominant Position in Canadian GLP-1 Market:** Company holds a commanding share among early filers, with high likelihood of adoption by all approved Canadian customers. * **New Pen Injector Contracts Signed:** One with an existing customer for a new project, another with a **completely new customer**, expanding client diversity. * **Strong U.K. Project Pipeline:** **7 new projects underway**, each with multi-customer potential, though constrained by current resourcing capacity. * **Emerging Market Traction:** **Three to four major partnerships** established in Turkey and Brazil, indicating strong foundation for regional market share capture. ## D. Launch Timelines * **India Launch Imminent:** **Harmony** set to go live in March; **Neo** to follow within first three months of launch window (March–May). * **Turkey & Brazil Launches Likely in H1 Next Year:** High probability of launches in **Q1**, with delays unlikely beyond **Q2**; no official client confirmation yet. * **Consumer Electronics Go-Live in 12–18 Months:** Commercial supply expected by end of FY26 or early FY27, pending final qualification. * **Delayed Milestone Recognition:** Certain **Q3 revenue milestones deferred to Q4**, causing temporary revenue recognition lag despite cost incurrence. * **Long Lead Times for Innovator Clients:** Launches require **2–3 years** from agreement to commercialization, dependent on molecule success. ## E. Order Visibility * **Partial Near-Term Visibility:** While **50–60% of India’s 50M-unit expansion** is contracted, most orders remain demand-driven, creating volatility in volume and revenue stability. * **Rolling Forecasts Prevail:** Limited long-term commitments; many customers provide only **52-week rolling forecasts**, reinforcing execution risk. --- # 6. Risks & Operational Constraints ## A. Key Figures * **COGS per Pen:** **USD 6 to USD 8** (includes fill/finish, device, and associated costs) * **Price Erosion on Pens:** **10% to 15%** on initial high-volume contracts, typical in early commercial phases * **Major Global Players in GLP-1 Devices:** **4** (excluding restricted Chinese entrants) ## B. Line Qualification Delays * **Production Bottleneck:** Supply constrained by delayed qualification of high-speed manufacturing line, despite strong demand. * **Complex Qualification Process:** Multi-phase cycle involving component testing, site audits, and system validation prolongs ramp-up for new suppliers. * **Ongoing Start-Up Challenges:** Amit Sanghvi confirms unresolved technical complexities have pushed back qualification timeline beyond original targets. ## C. Supply-Demand Gap * **Capacity-Linked Growth:** Scale-up in semiconductor casing supply dependent on operational readiness of Indian chip fabs. * **Structural Supply Constraint:** Only a handful of players meet precision requirements, reinforcing entry barriers and strategic positioning. * **Persistent Demand-Supply Imbalance:** GLP-1 device demand to outstrip supply over next 12–18 months due to limited global capacity. ## D. Pricing Pressures * **Moderate Pen Price Erosion:** Initial contract pricing reflects **10–15%** reduction, driven by competitive market share battles, not weak demand. * **Device Complexity Supports Pricing Power:** Pen component remains technically challenging, insulating it from severe erosion seen in commoditized **API** segments. * **COGS Clarification:** **USD 6–8** refers to total cost of goods sold per pen, not selling price, encompassing device, fill/finish, and ancillary costs. ## E. Geopolitical Factors * **Localization Driven by Logistics Costs:** High shipping expenses necessitate regional manufacturing close to end markets. * **Uncertain Impact from IKEA Sourcing Shifts:** No confirmed changes despite reports of increased U.S. sourcing; monitoring ongoing. * **Competitive Litigation Risk:** Him & Hers faces significant hurdles launching oral GLP-1, with low probability of market entry per management. * **Intensifying End-Market Competition:** High number of **Semaglutide** filers driving aggressive pricing strategies despite supply shortages. --- # 7. Guidance & Outlook ## A. Key Figures * **Pens Volume Guidance:** **~3 Cr units** for FY '26 (slightly lower due to 3-month delay) * **Capex Funding Mix:** **Internal accruals and debt** for Abu Dhabi facility (18-month timeline) * **Tariff Context:** **15–18% tariff range** cited, with potential competitive implications for exports ## B. Volume Projections * **Near-Term Revenue Recovery:** Q4 expected to benefit from non-recurring exhibition expenses and delayed Q3 revenue recognition. * **Cautious Growth Outlook:** Mid-single-digit consumer business growth remains uncertain pending **EU ratification** and **India-U.S. trade developments**; no volume guidance yet for 2027–28. * **Pens Volume Target Maintained:** FY '26 guidance remains broadly unchanged despite near-term qualification delays. ## C. Margin Recovery * **Healthcare Margin Trajectory:** Margins expected to improve with **scale, operational stabilization, and full automation**, despite lower pricing at higher volumes. * **Near-Term Margin Normalization:** Q1 margins projected to return to prior levels, supported by GLP-1 device scaling; Q4 to see limited high-speed production impact. ## D. Market Expansion * **Export Advantage Pending Approvals:** Business improvement anticipated in coming quarters if **U.S. FDA agreement** and **EU FTA** are implemented. * **International Launch Strategy:** Global rollout expected via partners post-India launch, with **Canada prioritized for volume**; potential for rapid expansion across 50–200 countries through COPP alignment. * **Confidence in Shaily Business Plan:** Capacity expansion under way with strong demand outlook, despite expected low initial utilization.